Quarsten et al., 2021 - Google Patents
Tick-borne pathogens detected in the blood of immunosuppressed Norwegian patients living in a tick-endemic areaQuarsten et al., 2021
- Document ID
- 9787431846413245793
- Author
- Quarsten H
- Salte T
- Lorentzen Ã
- Hansen I
- Hamre R
- Forselv K
- Øines Ã
- Wennerås C
- Noraas S
- Publication year
- Publication venue
- Clinical Infectious Diseases
External Links
Snippet
Background The knowledge regarding the occurrence and the clinical implications of tick- borne infections in immunosuppressed patients living in tick-endemic areas is limited. Methods Adult patients with autoimmune conditions requiring immunosuppressive treatment …
- 230000001717 pathogenic 0 title abstract description 38
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Quarsten et al. | Tick-borne pathogens detected in the blood of immunosuppressed Norwegian patients living in a tick-endemic area | |
| Mtei et al. | High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania | |
| Everett et al. | Human ehrlichiosis in adults after tick exposure: diagnosis using polymerase chain reaction | |
| de Jong et al. | Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in The Gambia | |
| Romero-Olmedo et al. | Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults | |
| Boden et al. | Borrelia miyamotoi–associated neuroborreliosis in immunocompromised person | |
| Bellete et al. | Evaluation of a whole-blood interferon-γ release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations | |
| Archibald et al. | A hospital-based prevalence survey of bloodstream infections in febrile patients in Malawi: implications for diagnosis and therapy | |
| van der Hoek et al. | Follow-up of 686 patients with acute Q fever and detection of chronic infection | |
| Carrara et al. | Use of a T cell–based assay for monitoring efficacy of antituberculosis therapy | |
| Kim et al. | Rapid diagnosis of tuberculous meningitis by T Cell—based assays on peripheral blood and cerebrospinal fluid mononuclear cells | |
| Brock et al. | Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-γ test | |
| Jarvis et al. | Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa | |
| Nicol et al. | Enzyme-linked immunospot assay responses to early secretory antigenic target 6, culture filtrate protein 10, and purified protein derivative among children with tuberculosis: implications for diagnosis and monitoring of therapy | |
| Bakken et al. | The serological response of patients infected with the agent of human granulocytic ehrlichiosis | |
| Lalvani | Counting antigen-specific T cells: a new approach for monitoring response to tuberculosis treatment? | |
| Bentley-Hibbert et al. | Pathophysiology of antigen 85 in patients with active tuberculosis: antigen 85 circulates as complexes with fibronectin and immunoglobulin G | |
| Cárcamo et al. | Etiologies and manifestations of persistent diarrhea in adults with HIV-1 infection: a case-control study in Lima, Peru | |
| Geisler et al. | Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection | |
| Telford et al. | Human granulocytic ehrlichiosis in Massachusetts | |
| Tantalo et al. | Treponema pallidum strain-specific differences in neuroinvasion and clinical phenotype in a rabbit model | |
| Godfrey et al. | Blood culture negative endocarditis in the modern era of 16S rRNA sequencing | |
| Ogrinc et al. | Suspected early Lyme neuroborreliosis in patients with erythema migrans | |
| Carpenter et al. | The incidence of ehrlichial and rickettsial infection in patients with unexplained fever and recent history of tick bite in central North Carolina | |
| Sester et al. | Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy |